

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: October 23, 2009
Electronic Signature for Brian C. Trinke, Ph.D.: /Brian C. Trinke/

Docket No.: EISN-018CP
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kenichi Chiba *et al.*

Application No.: 10/657,910

Confirmation No.: 5169

Filed: September 9, 2003

Art Unit: 1625

For: **MACROCYCLIC COMPOUNDS USEFUL
AS PHARMACEUTICALS**

Examiner: T. V. Oh

MS After Final
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

Dear Madam:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicants have become aware of the following documents, cited in a Japanese Office Action issued July 15, 2009, during the prosecution of Application No. 2003-574642, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submit these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the Office Action and of each document required under 37 CFR 1.98(a)(2) cited thereon are enclosed as well.

Please note that Applicants' attorney does not include in this Supplemental Information Disclosure Statement references EP 0606044, WO 96/13259, WO 00/38674, JP 8-40893, Agatsuma, "Revised Structure...", and Takehana, "A Radicicol-Related..." cited in the corresponding Office Action. These references were previously submitted in an Information Disclosure Statement to the U.S. Patent Office in this case on July 12, 2004.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

This Supplemental Information Disclosure Statement is filed after the mailing date of a Final Office Action but before payment of the Issue Fee (37 CFR 1.97(d)). Applicants hereby petition that the Supplemental Information Disclosure Statement be considered.

I hereby certify, pursuant to 37 CFR 1.97(e)(1), that each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. EISN-018CP.

Dated: October 23, 2009

Respectfully submitted,

BCT/DFC/mch

Electronic signature: /Brian C. Trinke/
Brian C. Trinke, Ph.D.
Registration No.: 56,593
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant